DYN
Dyne Therapeutics Inc
NASDAQ: DYN · HEALTHCARE · BIOTECHNOLOGY
$18.21
-1.14% today
Updated 2026-09-11
Market cap
$3.58B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.26
Dividend yield
—
52W range
$12 – $27
Volume
2.6M
WallStSmart proprietary scores
35
out of 100
Grade: D
Sell
Investment rating
4.3
Growth
C6.5
Quality
B3.0
Profitability
D6.7
Valuation
B3/9
Piotroski F-Score
Weak
0.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$39.86
+118.89%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
3 Strong Buy13 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.03x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Altman Z 0.93 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-131.80M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-165.24M | $-235.94M | $-317.42M | $-446.21M | $-178.56M |
| EPS | — | — | — | — | $-3.26 |
| Free cash flow | $-156.71M | $-188.89M | $-294.75M | $-405.13M | $-131.80M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Dyne Therapeutics Inc trades at $18.21. Our Smart Value Score of 35/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 0.93, it sits in the distress.
Frequently asked questions
What is Dyne Therapeutics Inc's stock price?
Dyne Therapeutics Inc (DYN) trades at $18.21.
Is Dyne Therapeutics Inc overvalued?
Dyne Therapeutics Inc carries a Smart Value Score of 35/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Dyne Therapeutics Inc (DYN)?
The 12-month analyst consensus target is $39.86, about 118.9% above the current $18.21. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Dyne Therapeutics Inc's Altman Z-Score is 0.93, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-58.90%
Beta1.08
50D MA$24.75
200D MA$19.91
Shares out0.19B
Float0.19B
Short ratio—
Avg volume2.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—